Form 4 for ELVN Enliven Therapeutics, Inc.

Accepted 2024-07-31 00:00:00 ET · period of report 2024-07-29 · accession 0001415889-24-020476 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2024-07-31	2024-07-29	ELVN	Lyssikatos Joseph P	CSO	S - Sale	$26.70	-12.0K	1.09M	-1%	-$320.4K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-07-29	S	D	11,797	$26.69	1,093,238	I See footnote	—	—	(F2) This transaction was executed in multiple trades at prices ranging from $26.3755 to $27.285. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
2	Common	Common Stock	2024-07-29	S	D	203	$27.43	1,093,035	I See footnote	—	—	(F4) This transaction was executed in multiple trades at prices ranging from $27.3814 to $27.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.